Study of the Efficiency of the Hydroporation for Delivery of Plasmid DNA to the Cells on the Model of Toxic Neuropathy
- Authors: Yudin M.A.1, Bykov V.N.1, Nikiforov A.S.1, Al-Shekhadat R.I.2, Ivanov I.M.1, Ustinova T.M.1
-
Affiliations:
- State Research Testing Institute of Military Medicine, Ministry of Defense of the Russian Federation
- InnovaBio Company
- Issue: Vol 164, No 6 (2018)
- Pages: 798-802
- Section: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/239922
- DOI: https://doi.org/10.1007/s10517-018-4083-0
- ID: 239922
Cite item
Abstract
We compared the efficiency of delivery of plasmid DNA (active ingredient concentration 1 mg/kg) that provides production of nerve growth factor (NGF) after intravenous administration to rats and after administration by hydroporation. The method of hydroporation ensured plasmid penetration into the liver tissue and lengthened the time of its detection in the organ. DNA concentration in 1 h after its introduction by hydroporation or intravenous route was 0.7 and 0.05 ng/mg tissue, respectively. The use of this transfection method ensured preservation of NGF DNA in the liver tissue at a level of 0.24 ng/mg of tissue 1 day after administration of the plasmid construct, while after intravenous administration, expression of the analyzed DNA was not detected in blood and liver samples. After hydroporation, the maximum of relative normalized expression of cDNA (270 rel. units) was observed after 4 h, and after 1 day, this parameter decreased to 35 rel. units. Introduction of plasmid DNA of NGF by hydroporation prevented the development of disorders of neuromuscular conduction in a rats model of toxic neuropathy induced by subacute administration of malathion in a dose of 0.5 LD50.
About the authors
M. A. Yudin
State Research Testing Institute of Military Medicine, Ministry of Defense of the Russian Federation
Author for correspondence.
Email: gniii_vm2@mil.ru
Russian Federation, St. Petersburg
V. N. Bykov
State Research Testing Institute of Military Medicine, Ministry of Defense of the Russian Federation
Email: gniii_vm2@mil.ru
Russian Federation, St. Petersburg
A. S. Nikiforov
State Research Testing Institute of Military Medicine, Ministry of Defense of the Russian Federation
Email: gniii_vm2@mil.ru
Russian Federation, St. Petersburg
R. I. Al-Shekhadat
InnovaBio Company
Email: gniii_vm2@mil.ru
Russian Federation, St. Petersburg
I. M. Ivanov
State Research Testing Institute of Military Medicine, Ministry of Defense of the Russian Federation
Email: gniii_vm2@mil.ru
Russian Federation, St. Petersburg
T. M. Ustinova
State Research Testing Institute of Military Medicine, Ministry of Defense of the Russian Federation
Email: gniii_vm2@mil.ru
Russian Federation, St. Petersburg